MedPath

ong term observational study on efficiency of a TNF-alpha blocker therapy on nail psoriasis in patients with moderate to severe plaque psoriasis or psoriatic arthritis

Conditions
L40
L40.5
Psoriasis
Arthropathic psoriasis
Registration Number
DRKS00016894
Lead Sponsor
Abbott GmbH & Co. KG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
755
Inclusion Criteria

moderate to severe psoriasis (with PASI, BSA or DLQI > 10)

Exclusion Criteria

Any other skin diseases that could interfere with the evaluation of psoriasis severity or other forms of psoriasis than plaque-type, onychomycosis, latent or active tuberculosis, hepatitis B and C, HIV infection as well as inability to understand the questionnaires and adhere to the trial procedures

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath